Category Archives: Transhuman News

PORTLAND, Ore., Feb. 28, 2017 /PRNewswire/ -- This year, the National Psoriasis Foundation (NPF) celebrates 50 years of patient support, advocacy, research funding, education and outreach to the more than 8 million individuals living with psoriasis and psoriatic arthritis. Originally formed in 1966 as The Psoriasis Society of Oregon, and officially becoming the National Psoriasis Foundation in 1967, its mission is focused on driving efforts to cure psoriatic disease and dramatically improving the lives of those affected.

Throughout its first 50 years, NPF has made significant contributions in advancing the research of life-changing treatments that have helped millions of people. From the tar-based procedures and topical creams to the revolutionary biologic treatments that exist today, NPF has always supported innovative approaches to treating psoriasis and psoriatic arthritis. While these achievements are to be celebrated, there is still much work to be done to improve access to treatments and, ultimately, to find a cure.

"We have only scratched the surface of what could be possible in treatingand ultimately curingpsoriasis and psoriatic arthritis. Advancements in psoriatic disease research are happening all the time, and NPF remains committed to funding this research while offering programs and services that support even more patients," said Dr. Colby Evans, M.D., National Psoriasis Foundation board chair. "I am honored to be associated with an organization that has always been at the forefront of driving efforts to find a cure for psoriasis and psoriatic arthritis."

NPF has achieved many milestones over the past 50 years, including securing for the first time ever, line-item funding in a federal budget for skin disease research, successfully lobbying the U.S. Food & Drug Administration for the approval of methotrexate for the treatment of severe psoriasis and opening the world's first support center providing free personalized assistance for people with psoriatic disease. Most recently, members of the NPF Medical Board issued the first paper in the United States that outlines psoriasis treatment targets and goals for individuals and health care providers to work on together to achieve clear skin and ultimately reduce the burden of the disease.

"NPF has been a pioneer in supporting research efforts that have led to the groundbreaking treatments used today," said Randy Beranek, president and CEO of the National Psoriasis Foundation. "During our 50th year, we are excited to recognize the people and milestones that have contributed so much to the psoriatic disease community, and remain committed to supporting research efforts towards finding a cure and dramatically improving the health outcomes of all affected by psoriasis and psoriatic arthritis."

In remaining true to its mission, the theme of the NPF 50th Year Celebration is "Driving Discovery, Creating Community." This allows the Foundation to celebrate the achievements of the past 50 years and to recognize the individuals and milestones that have made significant contributions to the psoriatic disease community. To recognize its 50th year, NPF will be holding events throughout the year, starting with a formal celebration on June 8, 2017, at the Plaza Hotel in New York City, and followed by the National Volunteer Conference and Research Symposium August 4 6, 2017 in Chicago, IL, as well as various TeamNPF events across the country.

Read More

During this year of celebration, NPF is committed to raising $2 million to fund several promising areas of research and programing, specifically early career research. Supporting the NPF 50th year campaign will ensure that researchers studying psoriatic disease will have the resources needed to turn their questions and theories into a cure.

To learn more about the NPF 50th Year Celebration and how to get involved, visit: https://www.psoriasis.org/NPF50th.

Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world's leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-psoriasis-foundation-celebrates-50-years-of-patient-support-advocacy-research-education-and-outreach-300414766.html

Go here to see the original:
National Psoriasis Foundation Celebrates 50 Years of Patient Support, Advocacy, Research, Education and Outreach - Yahoo Finance

INDIANAPOLIS , Feb. 28, 2017 /CNW/ --Eli Lilly and Company (LLY) will highlight new Phase 3 data evaluating Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the American Academy of Dermatology (AAD), which will take place March 3-7, 2017 , in Orlando, Fla.

Lilly will present 14 abstracts, including one oral late-breaker presentation highlighting head-to-head data on the efficacy and safety of Taltz compared to Stelara* (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis at 24 weeks.

"As the world's largest dermatology meeting, the American Academy of Dermatology annual meeting is an opportunity to highlight new information and data to experts in the dermatologic disease field," said Dr. Lotus Mallbris, global brand development leader, Taltz, Eli Lilly and Company. "Nearly one year after the approval of Taltz in the U.S. and Europe , we are proud to bring new data further demonstrating the efficacy and safety of Taltz to the American Academy of Dermatology annual meeting."

Studies, as well as the times and locations of the data sessions, are highlighted below.

Oral Late-Breaker Presentation

Saturday, March 4

Poster Presentations

Sunday, March 5

Indications and UsageTaltz (ixekizumab) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONSInfectionsTaltz may increase the risk of infection. The Taltz group had a higher rate of infections than the placebo group (27% vs. 23%). Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Patients receiving Taltz should be monitored closely for signs and symptoms of active TB during and after treatment.

HypersensitivitySerious hypersensitivity reactions, including anaphylaxis, angioedema and urticaria, have been reported with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel DiseaseCrohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease.

ImmunizationsPrior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Live vaccines should not be given with Taltz.

ADVERSE REACTIONSMost common adverse reactions (>1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

Please see accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.

IX HCP ISI 18JAN2017

About Taltz (ixekizumab)Taltz (ixekizumab) is an IgG4 monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines.

About Moderate-to-Severe Plaque PsoriasisPsoriasis is a chronic, immune disease that affects the skin.1 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells.Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate-to-severe plaque psoriasis.1,[2] Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease.1 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.1

Read More

AboutEli Lillyand CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us atwww.lilly.comandnewsroom.lilly.com/social-channels.

P-LLYThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for moderate-to-severe plaque psoriasis, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Taltz will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

_____________________________ 1 Psoriasis media kit. National Psoriasis Foundation website. https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf. Accessed February 23, 2017 . 2 Psoriasis. American Academy of Dermatology website. https://www.aad.org/media-resources/stats-and-facts/conditions/psoriasis. Accessed February 23, 2017 .

Refer to: Jen Dial ; dial_jennifer_kay@lilly.com; 317-220-1172 (Lilly Bio-Medicines)

* Lilly USA , LLC 2017. All rights reserved. Taltz is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. Stelara is a registered trademark owned or licensed by Janssen Pharmaceutical Companies of Johnson & Johnson, its subsidiaries or affiliates.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lilly-to-present-new-data-for-taltz-ixekizumab-in-psoriasis-and-psoriatic-arthritis-at-the-american-academy-of-dermatology-aad-annual-meeting-300414834.html

SOURCE Eli Lilly and Company

To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/February2017/28/c5919.html

Read the rest here:
Lilly to Present New Data for Taltz (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of ... - Yahoo Finance

New Delhi: Psoriasis, a skin condition in which skin cells build up and form scales and itchy, dry patches, has high chances of recurrence if the patient is subject to anxiety and depression, say doctors.

According to the doctors, stigma attached to the skin disease also contributes towards its recurrence. Nearly 84 per cent people suffering from moderate-to-severe psoriasis face discrimination and humiliation, with at least 40 per cent of them witnessing unwelcoming glares in public spaces.

Psoriasis has a significant impact on a patients quality of life. As long as there is a stigma attached to these conditions, patients will continue to have flare ups induced by emotional distress as anxiety and depression are major causes of psoriasis recurrences, Rajiv Sekhri, Consultant Dermatologist at Fortis hospital said on Wednesday.

The doctors also said that at least 18 per cent of the patients have been frequently asked whether their condition is communicable, pointing to a grave lack of awareness on the disease.

Psoriasis is a skin condition that changes the life cycle of skin cells. It causes cells to build up rapidly on the surface of the skin. The extra skin cells form thick, silver scales and itchy, dry, red patches that are sometimes painful. It is a persistent, long-lasting disease.

Stating that the psoriasis can affect personal lives and mental health, Sekhri said a survey conducted last year showed 36 per cent people admitted to feeling ashamed of their skin and the way they look.

Forty eight per cent of the patients interviewed shared that psoriasis has impacted their professional life and 30 per cent of them feel that psoriasis has impacted past or current relationships. These results reflect lack of hope and self-esteem, with 31 per cent of people stating that they do not believe clear or almost clear skin is an achievable goal for them, said Sekhri quoting the global survey of 8,300 people with psoriasis.

Sonal Soin, Medical Director and founder of city based Aayna Clinic said that awareness as well as acceptance is very low for psoriasis among patients as well as society.

Most of the people think it is contagious and avoid shaking hands or eating with patients suffering from the condition. Psoriasis is not contagious, one cannot pass the skin condition from one person to another, she said.

Creating awareness about psoriasis can help improve the quality of life of psoriasis patients, Soin added.

Link:
'Psoriasis likely to recur if patients have anxiety, depression' | The ... - The Siasat Daily

LONDON, Feb. 28, 2017 /PRNewswire/ --

Details Psoriasis Drugs Your Guide to R&D, Opportunities and Potential Revenues What does the future hold for treating psoriasis? Visiongain's new report gives you multilevel revenue forecasts from 2016, helping you stay ahead in data. There you see financial results, R&D trends, opportunities and potential revenues.

Download the full report: https://www.reportbuyer.com/product/4031803/

In our study you examine predicted sales to 2026 at overall world market, submarket, product and national level. You also assess technologies, competitive forces and expected products. That work's purpose is to help you avoid falling behind in knowledge, missing business or losing influence.

So read on now to explore that industry and discover what its future market could be worth. See how our investigation can benefit your work.

Forecasts from 2016 to 2026 and other analyses to help you harness opportunities Why miss data you need? Why struggle to find it? Instead let our analysis guide you through the psoriasis drug market's present and future. That understanding could bring you quicker, easier results, also benefiting your influence and reputation for business insight.

Besides revenue forecasting to 2026, our new work shows you recent results, growth rates and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). In our 169 page study you gain 74 tables and 63 charts to benefit your research, analyses, plans, decisions and presentations.

The following sections outline what you get in our updated investigation.

Sales predictions for the world market and submarkets What is that industry's potential? Discover in our report overall world revenue to 2026 for psoriasis-treating medicines. First you see individual revenue forecasts to 2026 for three main submarkets at world level: - Biological drugs - Topical treatments - Small-molecule systemic therapies.

How will those segments' revenues expand? Which classes of treatment will generate most sales? There you assess prospects for revenue growth, seeing where you can gain, assessing how that industry will compete and develop.

You find revenue predictions by product, too, seeing from 2016 how they can succeed.

Revenue predictions for 13 products to 2026 discover what their futures hold How will individual drugs perform from 2016 to 2026 at world level? Our report forecasts revenues of established brands and medicines expected from 2016.

In our work you assess 13 drugs, including these brands: - Humira (adalimumab) - Stelara (ustekinumab) - Enbrel (etanercept) - Remicade (infliximab) - Otezla (apremilast)

There you discover how high sales can go, to 2026, finding drugs and years with highest predicted growth and revenues. You also examine trends and competition. You see what is happening, understanding challenges, progress, competitors and opportunities.

You find geographical revenue predictions too.

National markets where will highest revenues and growth occur? In developed and developing countries, opportunities in psoriasis treatment will occur from 2016. You see where and how pharma companies can develop and gain.

Our analyses show individual revenue forecasts to 2026 for these 11 national markets: - US and Japan - France, Germany, Italy, Spain and UK - Brazil, Russia, India and China.

There you find countries with highest revenues and potential sales growth. You assess that technology's future, seeing progress and finding what it means, including emerging trends for those skin disorder treatments.

Events affecting developers, producers and sellers issues shaping that industry Our report explains forces affecting that industry and market from 2016, including these influences: - Research and development, including monoclonal antibodies, IL-12, IL-17, IL-23, PDE4, TNF, JAK and T-cell inhibition, and histamine receptor antagonism - Prevalence of that skin disease, as well as issues for patients and healthcare providers assess treatment needs - Competition from generic drugs, biosimilars and new biologics - Companies specialising in dermatology and autoimmune disorders explore capabilities and emerging trends to treat psoriasis - Advances in drug delivery to benefit companies, patients and payers, including lotion, ointment and foam.

In our survey you explore political, economic, social and technological questions, assessing outlooks for business. You also examine that pharmaceutical segment's strengths, weaknesses, opportunities and threats.

That way you discover what the present and future hold, seeing what is possible for those drug developers, producers and marketers. Stay ahead in knowledge.

Companies leading that industry and our overall revenue prediction for 2020 From 2016, treatments for psoriasis hold potential for investments, medical advances and higher revenues. Our work predicts the overall world market for psoriasis medicines will reach $11.4bn in 2020, with further expansion to 2026.

See what is possible there the expected gains. Our report shows you what technologies and firms hold greatest potential. You explore activities of these companies, among others: - Johnson & Johnson - AbbVie - Amgen - Pfizer - Novartis - Celgene - LEO Pharma.

Our analysis shows you participants' results, capabilities, developments and outlooks. R&D in that industry is strong. From 2016 the psoriasis market holds many opportunities for revenue growth. Our work explains that potential, helping you stay ahead in knowledge.

Main ways Psoriasis Drugs Market Forecasts 2016-2026 helps your work In particular our new investigation gives you these advantages to benefit your research, analyses, decisions, proposals and presentations: - Revenues to 2026 at world level, with forecasting of 3 submarkets and 13 products assess prospects for investments and sales growth - Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia investigate leading countries for revenues and expected sales - Forces driving and restraining that industry's expansion discover what influences revenue gain, finding trends, developments and opportunities - Prospects for established competitors and rising companies explore companies' portfolios, results, R&D and outlooks for future success.

Information found nowhere else: see how you can gain why miss out? Our investigation gives you independent analysis. There you gain business intelligence found only in our work, finding where opportunities for revenue expansion exist.

See in our work how you could benefit your research, analysis and decisions. Explore progress and possibilities. Also find how you could save time and benefit your authority on those drugs, helping your reputation for commercial insight.

Medicines for psoriasis get revenue predictions now, seeing what the future holds Our new report is for everyone investigating drugs for inflammation and skin disorders. In our survey you explore revenue forecasts to 2026, with discussions and other data. Avoid missing out in knowledge instead please get our report here now. Download the full report: https://www.reportbuyer.com/product/4031803/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/psoriasis-drugs-market-forecasts-2016-2026-300414898.html

More here:
Psoriasis Drugs Market Forecasts 2016-2026 - Yahoo Finance